INTRODUCTION {#s1}
============

Polycystic kidney disease (PKD) is the most common hereditary renal disease and the fourth most common cause of end-stage renal disease (ESRD) \[[@R1], [@R2]\]. Although most patients exhibit progressive renal injury, the average age of onset of ESRD and survival rates in ESRD have increased \[[@R3]\]. The major causes of death are cardiovascular diseases, infection, and central nervous system disorders; whereas uremia was the cause of death in only 2.2% of the patients \[[@R4]\]. Thus, the contribution of extrarenal manifestations such as liver cysts and cardiac disease to morbidity and mortality are increasingly recognized \[[@R5]\].

Among patients with autosomal dominant PKD (ADPKD), approximately 75%--90% have associated polycystic liver cysts (PLD) \[[@R6]\]. Polycystic liver disease (PLD) persists after ESRD and is a major feature in patients with PKD. PLD accounts for 10% of deaths in patients with ADPKD on hemodialysis \[[@R7]\]. Considerable improvements in radiological and surgical managements for cystic complications have been made in PKD patients with PLD \[[@R8]\]. However, more than 60% of patients with ADPKD present with abdominal pain, which has a detrimental effect on quality of life (QOL) \[[@R9], [@R10]\]. Anemia, low serum albumin level, ascites, and abdominal distention related to total liver and kidney volumes have a significantly negative influence on the QOL of patients with PKD \[[@R11]\]. Thus, the management of abdominal symptoms is important for improving the QOL of patients with PKD.

Abdominal pain and distention remain a diagnostic challenge in patients with PKD because renal and nonrenal sources of pain unrelated cystic complications must be considered \[[@R8]\]. Acute and chronic intra-abdominal complications such as inflammation, infection, and bleeding may manifest abdominal symptoms in PKD; this phenomenon has not been fully evaluated. The present study investigated the risk and outcome of hepatointestinal complications, including acute pancreatitis, cholangitis, peptic ulcer bleeding, and cirrhosis, beyond the conventional extrarenal manifestations in patients with PKD.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

Baseline demographic and comorbid characteristics of the PKD cohort were compared with those of the propensity-score (PS)-matched cohort (Table [1](#T1){ref-type="table"}). The mean age of the PKD cohort was 58.2 (SD: 17.0) years, and 3398 (56.3%) were men. Chronic kidney disease (CKD) was prevalent (32.4%), and 30.9% of the patients in the PKD cohort received maintenance dialysis. No significant differences in baseline characteristics were observed among the two cohorts.

###### Demographic characteristics and comorbidities of patients with and without polycystic kidney disease (propensity score-matched cohort)

                           Polycystic kidney disease                         
  ------------------------ --------------------------- ------ ------- ------ ------
  Age, year                                                                  0.99
   20-49                   2063                        34.2   8199    34.2   
   50-64                   1689                        28.0   6718    28.0   
   ≥ 65                    2279                        37.8   9059    37.8   
   Mean (SD)^\#^           58.2                        17.0   57.9    17.0   0.19
  Gender                                                                     0.98
   Female                  2633                        43.7   10471   43.7   
   Male                    3398                        56.3   13505   56.3   
  Comorbidity                                                                
   CKD                     1953                        32.4   7688    32.1   0.64
   ESRD                    1862                        30.9   7336    30.6   0.68
   GB stone disease        438                         7.26   1681    7.01   0.50
   Hyperlipidemia          591                         9.80   2295    9.57   0.59
   Obesity                 11                          0.18   27      0.11   0.17
   Diabetes                1110                        18.4   4382    18.3   0.82
   Alcoholism              66                          1.09   233     0.97   0.39
   Chronic HBV infection   213                         3.53   790     3.29   0.36
   Chronic HCV infection   202                         3.35   754     3.14   0.99
   NAFLD                   170                         2.82   643     2.68   0.56

Chi-square test; ^\#^: T-test.

HBV: Hepatitis B virus; HCV: Hepatitis C virus; NAFLD: Nonalcoholic fatty liver disease.

Primary outcomes {#s2_2}
----------------

The mean follow-ups for patients who developed acute pancreatitis, cholangitis, peptic ulcer bleeding, and cirrhosis in the PKD cohort were 4.64 ± SD: 3.58, 4.67 ± SD: 3.57, 4.43 ± SD: 3.57, and 4.57 ± SD: 3.57 years, respectively. Figure [2](#F2){ref-type="fig"} presents the risks of acute pancreatitis, cholangitis, peptic ulcer bleeding, and cirrhosis in terms of the Kaplan--Meier survival analysis for the PS-matched cohort followed up for more than 10 years. The risks were significantly higher in the PKD cohort than in the control cohort (log-rank test, *p* \< 0.001). Notably, the incidence of peptic ulcer bleeding was more prevalent than that of acute pancreatitis, cholangitis, and cirrhosis through the follow-up period.

During follow-up, 160 patients developed acute pancreatitis in the PKD cohort (Table [2](#T2){ref-type="table"}). The incidence rate of acute pancreatitis was higher in the PKD cohort than that in the control cohort (5.72 vs 2.37 per 1000 person-years), with an incidence rate ratio (IRR) of 2.41. In the multivariate model, the adjusted subhazard ratio (aSHR) of acute pancreatitis was 2.36-fold higher in the PKD cohort (95% confidence interval \[CI\], 1.95--2.84, *p* \< 0.001) than that in the control cohort.

###### Incidence and subhazard ratio of hepatointestinal complications for patients with and without polycystic kidney disease calculated in a competing risk (death) model

                          Polycystic kidney disease                                                                   
  ----------------------- --------------------------- ------- ------ ------ -------- ------ ------------------------- -------------------------
  Acute pancreatitis      160                         27972   5.72   302    127285   2.37   2.37 (1.97, 2.86)\*\*\*   2.36 (1.95, 2.84)\*\*\*
  Cholangitis             113                         28176   4.01   188    127621   1.47   2.27 (1.82, 2.83)\*\*\*   2.41 (1.93, 3.01)\*\*\*
  Peptic ulcer bleeding   532                         26700   19.9   1068   125502   8.51   2.42 (2.18, 2.68)\*\*\*   2.41 (2.17, 2.67)\*\*\*
  Cirrhosis               154                         28183   5.46   501    127143   3.94   1.41 (1.18, 1.69)\*\*\*   1.39 (1.16, 1.66)\*\*\*

PY, person-years; Rate\#, incidence rate per 1000 person-years.

Crude SHR†, relative subhazard ratio.

Adjusted SHR‡: Covariables found significantly associated with outcome diseases in the univariable competing risk (death) model were further examined using the multivariable competing risk (death) model.

\*\*\*p \< 0.001.

In the PKD cohort, 113 patients developed cholangitis with an incidence rate of 4.01 per 1000 person-years. The IRR was 2.72, and the PKD cohort had a 2.41-fold higher risk of cholangitis (95% CI, 1.93--3.01) than the control cohort. In an analysis of risk factors, alcoholism, gallstones, PKD, CKD, and increasing age were independently associated with acute pancreatitis and cholangitis (Table [3](#T3){ref-type="table"}).

###### Hazard ratios of outcome in association with sex, age, and comorbidities in univariable and multivariable competing risk (death) model

                                       Acute pancreatitis        Cholangitis               Peptic ulcer bleeding     Cirrhosis                                                                                               
  ------------------------------------ ------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ------------------------- -------------------------
  Polycystic kidney disease            2.37 (1.97, 2.86)\*\*\*   2.36 (1.95, 2.84)\*\*\*   2.27 (1.82, 2.83)\*\*\*   2.41 (1.93, 3.01)\*\*\*   2.42 (2.18, 2.68)\*\*\*   2.41 (2.17, 2.67)\*\*\*   1.41 (1.18, 1.69)\*\*\*   1.39 (1.16, 1.66)\*\*\*
  Gender (Women vs Men)                1.28 (1.07, 1.55)\*\*     1.17 (0.97, 1.41)         1.29 (1.07, 1.55)\*\*     1.17 (0.97, 1.41)         1.43 (1.29, 1.58)\*\*\*   1.38 (1.25, 1.53)\*\*\*   1.47 (1.25, 1.72)\*\*\*   1.31 (1.12, 1.53)\*\*\*
  Age, per year                        1.01 (1.01,1.01)\*\*\*    1.01 (1.01, 1.01)\*\*\*   1.01 (1.01, 1.02)\*\*\*   1.01 (1.01, 1.01)\*\*\*   1.04 (1.03, 1.04)\*\*\*   1.03 (1.03,1.04)\*\*\*    1.02 (1.02, 1.02)\*\*\*   1.02 (1.02, 1.02)\*\*\*
  Baseline comorbidities (yes vs no)                                                                                                                                                                                         
   CKD                                 1.78 (1.49, 2.13)\*\*\*   1.67 (1.28, 2.18)\*\*\*   1.77 (1.48, 2.12)\*\*\*   1.66 (1.27, 2.17)\*\*\*   2.25 (2.05, 2.48)\*\*\*   2.30 (2.01, 2.62)\*\*\*   2.56 (2.20, 2.97)\*\*\*   2.72 (2.20, 3.35)\*\*\*
   ESRD                                1.53 (1.28, 1.83)\*\*\*   1.08 (0.83, 1.41)         1.53 (1.28, 1.83)\*\*\*   1.08 (0.83, 1.42)         1.73 (1.58, 1.91)\*\*\*   0.92 (0.81, 1.05)         1.79 (1.55, 2.08)\*\*\*   0.78 (0.64, 1.00)
   GB stone disease                    4.16 (3.37, 5.13)\*\*\*   3.97 (3.21, 4.90)\*\*\*   4.11 (3.33, 5.07)\*\*\*   3.90 (3.16, 4.82)\*\*\*   1.06 (0.90, 1.25)         \-                        1.15 (0.89, 1.50)         \-
   Hyperlipidemia                      1.28 (0.98, 1.67)         \-                        1.28 (0.98, 1.67)         \-                        1.03 (0.88, 1.20)         \-                        0.80 (0.61, 1.04)         \-
   Obesity                             \-                        \-                        \-                        \-                        1.80 (0.45, 7.20)         \-                        \-                        \-
   Diabetes                            1.32 (1.06, 1.63)\*       1.22 (0.98, 1.51)         1.32 (1.06, 1.63)\*       1.22 (0.98, 1.51)         1.14 (1.02, 1.28)\*       1.12 (1.00, 1.26)         0.91 (0.74, 1.10)         \-
   Alcoholism                          5.66 (3.79, 8.44)\*\*\*   5.62 (3.71, 8.50)\*\*\*   5.39 (3.61, 8.05)\*\*\*   5.38 (3.56, 8.14)\*\*\*   1.87 (1.27, 2.76)\*\*     1.84 (1.25, 2.72)\*\*\*   4.96 (3.45, 7.15)\*\*\*   5.10 (3.52, 7.39)\*\*\*
   Chronic HBV infection               1.37 (0.88, 2.14)         \-                        1.39 (0.89, 2.17)         \-                        1.07 (0.80, 1.42)         \-                        3.71 (2.89, 4.75)\*\*\*   2.97 (2.31, 3.83)\*\*\*
   Chronic HCV infection               1.46 (0.94, 2.26)         \-                        1.47 (0.95, 2.27)         \-                        1.42 (1.11, 1.81)\*\*     1.19 (0.93, 1.52)         4.48 (3.56, 5.64)\*\*\*   3.46 (2.72, 4.39)\*\*\*
   NAFLD                               1.60 (1.05, 2.43)\*       1.18 (0.77, 1.81)         1.58 (1.04, 2.41)\*       1.21 (0.79, 1.86)         1.03 (0.79, 1.34)         \-                        1.03 (0.67, 1.57)         \-

† Crude SHR, relative subhazard ratio.

‡ aSHR: adjusted SHR. Covariables found significantly associated with outcome diseases in the univariable competing risk (death) model were further examined using the multivariable competing risk (death) model.

\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

HBV: Hepatitis B virus; HCV: Hepatitis C virus; NAFLD: Nonalcoholic fatty liver disease.

Of 6031, 532 (8.8%) patients developed peptic ulcer bleeding with an incidence rate of 15.9 per 1000 person-years in the PKD cohort. The patients with PKD had a higher risk of peptic ulcer bleeding (aSHR 2.41 \[95% CI, 2.17--2.67\]) compared with the control cohort (Table [2](#T2){ref-type="table"}). PKD, CKD, alcoholism, female sex, and increasing age were associated with an increased risk of peptic ulcer bleeding (Table [3](#T3){ref-type="table"}).

The prevalence of chronic hepatitis and alcoholism was balanced over the study and control cohorts. A total of 154 (2.5%) patients developed cirrhosis in the PKD cohort. The patients with PKD had a 1.41-fold higher risk of cirrhosis (95% CI, 1.37--2.39) compared with the controls (Table [2](#T2){ref-type="table"}). The presence of comorbidities such as alcoholism, chronic hepatitis B and C infection, CKD, PKD, female sex, and increasing age were associated with an increased risk of cirrhosis (Table [3](#T3){ref-type="table"}).

Secondary outcome: overall mortality {#s2_3}
------------------------------------

Kaplan--Meier analysis revealed an increased overall mortality in patients with PKD who developed acute pancreatitis and peptic ulcer bleeding compared with the controls (log-rank *p* \< 0.05; [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

This investigation represents a national cohort study to evaluate major hepatointestinal complications other than common cystic manifestations in patients with PKD. When patients with PKD present with acute abdominal pain or febrile illness, clinicians often focus on excluding diagnoses that are more prevalent in PKD, such as cyst infection, cyst rupture or hemorrhage, and nephrolithiasis \[[@R7], [@R12]\]. However, patients still experience non-cystic intra-abdominal complications. Our findings corroborate the results from a UK epidemiologic study of 23,454 patients with PKD, which reported that patients with PKD exhibited higher rates of admission for biliary tract disease and serious liver complications \[[@R13]\]. Nevertheless, our results differed from theirs in two aspects. First, female predominance influenced the risk of both biliary disease and cirrhosis in our study, whereas in their study, a higher risk of biliary tract disease was observed in men than in women, and a higher risk of serious liver complications was observed in women than in men. Second, the presence of CKD, but not ESRD, reinforced hepatointestinal risks in our study. In brief, the exceeding risk of hepatointestinal manifestations was evident in our study, and two complications, acute pancreatitis and peptic ulcer bleeding, contributed to an increased overall mortality in patients with PKD.

Acute pancreatitis and cholangitis in polycystic kidney disease {#s3_1}
---------------------------------------------------------------

Acute, chronic, or recurrent pancreatitis and cholangitis occurred in patients with ADPKD \[[@R14]--[@R16]\]. Pancreatitis in patients with PKD is caused by the obstruction of the pancreatic duct by the pancreatic cystic compression, leading to duct distortions and exocrine dysfunction of the pancreas \[[@R17]\]. The frequency of pancreatic cysts ranged from 9%--36% in patients with PKD \[[@R18]\]. According to our review of the relevant literature, pancreatic cyst complications in PKD have not been determined. Although patients with pancreatic cysts are usually asymptomatic, they could present with pancreatitis or pancreatic malignancies \[[@R19], [@R20]\].

Common bile duct dilation is prevalent (40%) in patients with PKD \[[@R21]\]. Dranssart et al. observed intrahepatic bile duct abnormalities in 27.8% of the patients with PKD, which correlated with the results of hepatobiliary infection \[[@R22]\]. A case report described the presence of multifocal cystic dilatation of the intrahepatic bile ducts, such as Caroli\'s disease, in patients with PKD \[[@R23]\]. Hasegawa et al. reported a patient with diagnostic imaging findings indicating hepatobiliary abnormalities of Caroli\'s disease and cystic dilated biliary ducts with stones in endoscopic retrograde cholangiography, which led to recurrent cholangitis with hepatobiliary stones \[[@R24]\]. These patients may experience recurrent fever and septicemia. Appropriate diagnosis of cholangitis is necessary because antibiotics and biliary stone extraction are indicated whenever feasible.

Because recurrent infections and complications related to hepatobiliary system abnormalities can be associated with morbidity, we proposed that pancreatitis and cholangitis should be considered in the differential diagnosis of febrile or abdominal pain as well as cyst infection in patients with PKD.

Peptic ulcer bleeding in polycystic kidney disease {#s3_2}
--------------------------------------------------

Peptic ulcer bleeding is a medical condition that results in high morbidity. Risk factors for peptic ulcers include painkiller use, alcohol consumption, older age, and medical illnesses such as diabetes and ESRD \[[@R25]--[@R27]\]. Patients with PKD who presented with Budd--Chiari syndrome were prone to gastrointestinal bleeding from the varices or portal hypertensive gastropathy \[[@R28]\]. However, data on the risk of peptic ulcer bleeding in patients with PKD are lacking.

In our study cohort, 65.8% patients were older than 50 years, and patients with concomitant diabetes or ESRD were prevalent, which might be attributed to the association between PKD and peptic ulcer bleeding. Another possible explanation may be the use of analgesics, including acetaminophen and possibly intermittent short courses of NSAIDs or cyclooxygenase-2 inhibitors, in patients with chronic pain syndrome \[[@R29]\]. Additional potential confounders, such as *Helicobacter pylori* infection status, smoking, and painkiller or proton pump inhibitor consumption, should be considered in future research to elucidate the relationship between peptic ulcer bleeding and PKD. Nonetheless, our results represent the first quantification of this association and highlight the impact of peptic ulcer bleeding on overall mortality in patients with PKD.

Liver cirrhosis in polycystic kidney disease {#s3_3}
--------------------------------------------

Until now, cirrhosis has been underrecognized in patients with PKD. Patients with PKD exhibit a relative loss of liver parenchyma in the late stages of the disease, with splenomegaly associated with liver cyst severity \[[@R30]\]. Some studies have reported patients with cirrhosis and have determined the mechanism of cirrhosis in patients PKD. Torres et al. reported patients with severe polycystic kidney or liver disease who developed Budd--Chiari syndrome characterized by ascites and hepatic venous outflow obstruction \[[@R28]\]. In patients with Budd--Chiari syndrome, the histological findings included centrilobular hepatocyte necrosis, obstructive portal venopathy, and cirrhosis \[[@R31], [@R32]\]. If left untreated, patients often die from intractable ascites, gastrointestinal bleeding, and liver failure. Ratcliffe et al. \[[@R33]\] reported an adult PKD patient with liver cysts who was diagnosed with portal hypertension complicated by bleeding esophageal varices. The authors proposed that hepatic dysfunction was caused by the replacement of hepatic parenchyma by cysts and compression of the portal vein by cysts contributing to portal hypertension.

Our result demonstrated an association between PKD and cirrhosis, and most patients with cirrhosis had concomitant chronic liver diseases. In addition, we demonstrated that alcoholism and concomitant chronic liver disease were independently associated with cirrhosis, which is consistent with other study results \[[@R34], [@R35]\]. Thus, we proposed that PKD patients with chronic liver disease or severe liver phenotype should be monitored for signs of liver decompensation. Early referral of these patients to hepatologists for evaluating the need for liver transplantation or combined liver or kidney transplantation is suggested \[[@R36]\].

Study limitations {#s3_4}
-----------------

Our study is a retrospective registry-based study. Although the results are robust and the large sample size provides adequate statistical power for detecting the risk in the follow-up period, limitations should be addressed. First, patients with cirrhosis were identified using diagnostic codes recorded in the inpatient claims from the National Health Insurance Research Database (NHIRD) by clinicians based on imaging, the Child--Pugh score, and pathology. Detailed clinical information such as laboratory data, pathology staging, and radiographic findings was unavailable in this database. Nevertheless, catastrophic illness certification for cirrhosis was issued by hepatology specialists using the standard criteria after peer review.

Second, the severity of PLD in the PKD cohort was not demonstrated in our study because of database limitation. However, according to our review of the relevant literature, no study has established either the staging system for PLD severity or the association between PLD severity and clinical outcome in patients with PKD. Third, because early stage PKD is usually asymptomatic and could be underdiagnosed in the control cohort, outcome risk may have been overestimated in the control cohort. Fourth, this study could not provide CKD staging information because of database limitations. Alternatively, we categorized renal dysfunction into CKD and ESRD in our cohorts and observed different risk contribution to outcome diseases (Table [3](#T3){ref-type="table"}).

MATERIALS AND METHODS {#s4}
=====================

Data source {#s4_1}
-----------

In this study, data were retrieved from the NHIRD, which is a nationwide electronic database containing the longitudinal medical records of beneficiaries enrolled in the National Health Insurance (NHI) program in Taiwan. The NHI program, launched on March 1, 1995, provides health care coverage to 99% of the population of Taiwan (approximately 23.75 million people). The NHIRD includes registries of enrolment files, diagnoses, procedures, drug prescriptions, and claims summaries of inpatients. Moreover, it includes the Registry of Catastrophic Illness Patients Database, which comprises 30 disease categories, including ESRD, cystic kidney disease, and cirrhosis. Beneficiaries of catastrophic illness certification are exempted from copayment for medical services. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) was used to define diseases. The diagnosis validity for diseases such as PKD, cirrhosis, acute pancreatitis, cholangitis, and peptic ulcer bleeding in medical publications from the NHIRD were credible \[[@R37]--[@R42]\]. Data validation demonstrated the high accuracy of the NHIRD in population-based studies \[[@R43], [@R44]\].

Ethics statement {#s4_2}
----------------

Patient records in the NHIRD are anonymized to protect patient privacy. This study was approved to fulfill the condition for exemption by the Institutional Review Board and the Ethics Committee of China Medical University (CMUH104-REC2-115-CR1). Informed patient consent was waived because the data used in this study were anonymized.

Study design and patient selection {#s4_3}
----------------------------------

This was a retrospective cohort study; Figure [1](#F1){ref-type="fig"} presents the study design. All inpatients with a primary diagnosis of PKD (ICD-9-CM codes 753.12 and 753.13) at admission between January 1, 2000, and December 31, 2010 were identified (*N* = 7149). Primary diagnosis of PKD included clinical symptoms, imaging studies, and family history. Among patients with PKD, 1118 were excluded on the basis of the following criteria: age less than 20 years; a history of acute pancreatitis (ICD-9-CM code 577.0), cholangitis (ICD-9-CM code 576.1), peptic ulcer bleeding (ICD-9-CM codes 531.0, 531.2, 531.4, 531.6, 532.0, 532.2, 532.4, 532.6, 533.0, 533.2, 533.4, and 533.6), and cirrhosis (ICD-9-CM codes 571.2, 571.5, and 571.6) prior to the index hospitalization; and missing information. A total of 6031 patients with PKD were enrolled as the study cohort. The control cohort comprised those who did not have a history of PKD, who were selected from the inpatient database by using the same exclusion criteria applied for the study cohort. The control cohort (*N* = 23,976) was PS-matched with the study cohort in a 1:4 ratio by sex, age, index date, and underlying comorbidities. The date of initial PKD diagnosis was defined as the index date.

![Flowchart of the cohort selection procedure](oncotarget-08-80971-g001){#F1}

![Cumulative incidence of acute pancreatitis **(A)**, cholangitis **(B)**, peptic ulcer bleeding **(C)**, and cirrhosis **(D)** in patients with and without polycystic kidney disease.](oncotarget-08-80971-g002){#F2}

Comorbidities {#s4_4}
-------------

Demographic information of the study and control cohorts was obtained, including the underlying comorbid illnesses, which were diagnosed in previous inpatient claims or at least three successive outpatients claims before the index hospitalization date. We identified CKD (ICD-9-CM code 585) and ESRD (ICD-9-CM code 586) as indicators of PKD severity. Factors that could affect outcome, such as alcoholism (ICD-9-CM codes 291, 303, 305.00--305.3, 571.0, 571.1, and 571.3) and calculus of gallbladder (ICD-9 codes 574.0, 574.1, 574.2, 574.6, 574.7, 574.8, and 574.9), hyperlipidemia (ICD-9 codes 272.1--272.4, 272.8, and 272.9) for acute pancreatitis; and alcoholism, chronic hepatitis B virus infection (ICD-9 codes 070.22, 070.23, 070.32, 070.33, and V02.61), chronic hepatitis C virus infection (ICD-9 codes 070.41, 070.44, 070.51, 070.54, and V02.62), and nonalcoholic fatty liver disease (ICD-9 code 571.8) for cirrhosis were also evaluated.

Outcomes {#s4_5}
--------

The primary outcomes were a diagnosis of acute pancreatitis, cholangitis, peptic ulcer bleeding, and cirrhosis during hospitalization in the follow-up period. Acute pancreatitis was mainly defined according to the Atlanta classification \[[@R45]\], with an inflammatory process of the pancreas with variable involvement of other local tissue and remote organ dysfunction. The classic triad of right upper quadrant pain, fever, and jaundice was used to define cholangitis. Primary diagnosis of peptic ulcer bleeding was made in patients who had undergone a panendoscopy (billing code: 47043B) during hospitalization. We excluded variceal hemorrhage (ICD-9 codes 456.0 and 456.20) related to cirrhosis. The follow-up period commenced from the index date until the occurrence of outcome, the date on which patients were censored because of withdrawal from the insurance program (e.g., death, immigration, and imprisonment), or end of the study period (Dec 31, 2011).

Statistical analysis {#s4_6}
--------------------

Demographics and comorbidities were compared between the study and control cohorts by using a chi-square test for dichotomous variables and Student\'s *t* test for continuous variables. Multivariate analyses were used to model outcome diseases after adjustment for potential confounders. The cumulative incidence of the outcome was calculated using the Kaplan--Meier method, and Cox proportional hazard regression models were used to identify the risks of outcome. Because death was a potential confounding factor and could have biased the estimation of outcome risk, we analyzed a competing risk model to estimate the SHRs and 95% CIs of the outcome incidence in both cohorts by using the Fine and Gray method \[[@R46]\]. SAS (version 9.3; SAS Institute, Inc., Cary, NC, USA) was used for all statistical analyses. A two-sided *P* value of \<.05 was considered statistically significant.

CONCLUSION {#s5}
==========

Our study demonstrated that PKD is associated with major hepatointestinal complications. The development of acute pancreatitis and peptic ulcer bleeding had a negative impact on overall mortality in patients with PKD. Therefore, acute pancreatitis and cholangitis should be listed in the differential diagnosis of acute abdominal pain in patients with PKD. For anemia survey in patients with PKD, peptic ulcer bleeding should be considered.

SUPPLEMENTARY MATERIALS FIGURES {#s6}
===============================

**Author contributions**

Conceptualization: STH, LBJ.

Methodology: CLL, LBJ.

Software: CLL, LBJ.

Validation: STH, TMY, CLL, LBJ.

Formal analysis: STH, TMY, CLL, LBJ.

Investigation: STH, LBJ.

Resources: STH, LBJ.

Data curation: STH, TMY, CLL, LBJ.

Writing (original draft preparation): STH, TMY, CLL, LBJ.

Writing (review and editing): STH, TMY, CLL, LBJ.

Visualization: STH, TMY, CLL, LBJ.

Supervision: LBJ.

Project administration: LBJ.

Funding acquisition: LBJ.

**CONFLICTS OF INTEREST**

The authors report no conflicts of interest.

**FUNDING**

This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004); China Medical University Hospital; Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037); NRPB Stroke Clinical Trial Consortium (MOST 105-2325-B-039-003); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.
